ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Estrella Immunopharma (ESLA)
Estrella Immunopharma stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$0.92▼ -6.64%
Prices as of Oct 26, 2026 · USD
Chance of rising in 1 month
39%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Estrella Immunopharma in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Estrella Immunopharma
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Estrella Immunopharma a 39% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $0.60 and $1.10; in 9 out of 10, between $0.35 and $1.90. Estimated annual volatility is 200%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $20.4M
- 52-week high
- $3.15
- 52-week low
- $0.31
- Revenue (12 months)
- $0.0M
- Return on equity
- 126.0%
- Free cash flow (12 months)
- $-6.8M
- Beta
- 0.89
What this means
ATLAS does not publish a fair value for ESLA right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks ESLA has traded between $0.31 and $3.15. Today it is 70.8% below that high and 197% above its low.
Its beta is 0.89: it moves roughly in line with the market.
About the company
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers, solid tumors, and certain autoimmune diseases.
Want to see everything about Estrella Immunopharma?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Estrella Immunopharma do?
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers, solid tumors, and certain autoimmune diseases.
What is the chance ESLA goes up next month?
39%: somewhat worse than a coin flip. In half of the simulated outcomes, ESLA ends the month between $0.60 and $1.10.
How big is Estrella Immunopharma and what is its P/E ratio?
Estrella Immunopharma's market capitalization is $20.4M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is ESLA?
ATLAS estimates annual volatility at 200%. In a typical month, half of the outcomes end between $0.60 and $1.10.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer